In this issue:
Leukaemia selection
• Monitoring of minimal residual disease in NPM1-mutated AML
• Chimeric antigen receptor-modified T-cells in CLL
• Nonmyeloablative conditioning with allogeneic HSCT for high-risk ALL
Lymphoma selection
• ABVD vs. BEACOPP for HL with planned high-dose salvage
• Reduced intensity allogeneic HSCT induces remission in relapsed HL
• Effects of statins, metformin and aspirin on rituximab-treated DLBCL
• Alemtuzumab in LPL/Waldenström macroglobulinaemia
• R-miniCHOP in elderly patients with DLBCL
• Bortezomib added to R-CVP in advanced-stage FL
• Bortezomib, bendamustine and rituximab in relapsed/refractory FL
Please login below to download this issue (PDF)